All In Biotech

Drug Trial Radar · NCT01420783

Study With SAR302503 in Patients With Polycythemia Vera or Essential Thrombocythemia

A Randomized Phase II, Open-Label Study of the Efficacy and Safety of Orally Administered SAR302503 in Patients With Polycythemia Vera (PV) or Essential Thrombocythemia (ET) Who Are Resistant or Intolerant to Hydroxyurea

Last checked: Nov 21, 2026Latest source record: Mar 5, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

81

Actual

Start

Oct 2011

Primary completion

Nov 2012

Study completion May 2014

Sponsor

Lead sponsor
Bristol-Myers SquibbBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Aug 22, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Primary Objective: * Dose Ranging Phase: To evaluate the efficacy of daily oral doses of 100, 200, and 400 mg SAR302503 in patients with PV and ET who are resistant or intolerant to hydroxyurea (per European LeukemiaNet criteria) for : * Inducing absence of phlebotomy and a hematocrit below 45% for a minimum of 3 months in patients with polycythemia vera, and * Reduction of platelet count to ≤400 x 10x9/L for a minimum of 3 months in patients with essential thrombocythemia. * PV Dose Expansion Phase and ET Dose Ranging Phase (only 600 mg dose group): To evaluate the efficacy of daily oral SAR302503 in patients with PV and ET who are resistant or intolerant to hydroxyurea (per European LeukemiaNet criteria) for: * Inducing absence of phlebotomy eligibility beginning at Day 1 of Cycle 4 visit and continuing through Day 1 of Cycle 6 visit in patients with PV, and * Reduction of platelet count to ≤400 x 10x9/L beginning at Day 1 of Cycle 4 visit and continuing through Day 1 of Cycle 6 visit in patients with ET. Secondary Objectives: * To evaluate the safety of SAR302503. * To evaluate the efficacy of SAR302503 in patients with PV who are resistant or intolerant to hydroxyurea for inducing absence of phlebotomy eligibility. * To evaluate the efficacy of SAR302503 in patients with ET who are resistant or intolerant to hydroxyurea for reduction of platelet counts. * To evaluate the efficacy of SAR302503 in inducing complete and partial responses beginning at Day 1 of Cycle 6 visit through Cycle 8. * To evaluate splenic response as measured by spleen volume using MRI or CT. * To evaluate the pharmacokinetics of SAR302503 after single and repeat doses. * To evaluate the pharmacodynamics of SAR302503 as measured by changes in JAK2V617F allele burden in patients with JAK2V617F mutation, and STAT3 phosphorylation inhibition. * To measure improvement in baseline myeloproliferative neoplasm (MPN)-associated symptoms, as well as overall impact on quality of life. * To measure generic health-related quality of life and utility value using the EuroQol Group (EQ-5DTM) questionnaire.

Conditions

  • Hematopoietic Neoplasm

Interventions

  • SAR302503Drug

    Pharmaceutical form:capsule Route of administration: oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose Ranging Phase: Proportion of PV patients with absence of phlebotomy and hematocrit below 45% and proportion of ET patients with a platelet count ≤ 400 x 10x9/L for a minimum of 3 months during the first 8 cycles of therapy.Time frame: 2 years
  2. PV Dose Expansion Phase: Proportion of PV patients with absence of phlebotomy eligibility beginning at Day 1 of Cycle 4 visit and continuing through Day 1 of Cycle 6 visit.Time frame: 2 years
  3. ET Dose Ranging Phase (only 600 mg dose group): Proportion of ET patients with a platelet count ≤400 x 10x9/L beginning at Day 1 of Cycle 4 visit and continuing through Day 1 of Cycle 6 visit.Time frame: 2 years

Locations

35 sites in 9 countries. Site status is shown where the registry gives one.

  • Investigational Site Number 840008

    Scottsdale, Arizona

  • Investigational Site Number 840004

    La Jolla, California

  • Investigational Site Number 840005

    Los Angeles, California

  • Investigational Site Number 840011

    Palo Alto, California

  • Investigational Site Number 840010

    Ann Arbor, Michigan

  • Investigational Site Number 840007

    Rochester, Minnesota

  • Investigational Site Number 840003

    St Louis, Missouri

  • Investigational Site Number 840001

    Houston, Texas

  • Investigational Site Number 036001

    Clayton, Australia

  • Investigational Site Number 036002

    Kingswood, Australia

  • Investigational Site Number 036004

    Kogarah, Australia

  • Investigational Site Number 036003

    Randwick, Australia

  • Investigational Site Number 124002

    Montreal, Canada

  • Investigational Site Number 124003

    Toronto, Canada

  • Investigational Site Number 124001

    Vancouver, Canada

  • Investigational Site Number 250004

    Brest, France

  • Investigational Site Number 250003

    Marseille, France

  • Investigational Site Number 250001

    Paris, France

  • Investigational Site Number 276004

    Frankfurt am Main, Germany

  • Investigational Site Number 276003

    Mannheim, Germany

  • Investigational Site Number 380003

    Bologna, Italy

  • Investigational Site Number 380001

    Florence, Italy

  • Investigational Site Number 380004

    Orbassano, Italy

  • Investigational Site Number 410001

    Seongnam, South Korea

  • Investigational Site Number 410003

    Seoul, South Korea

  • Investigational Site Number 410004

    Seoul, South Korea

  • Investigational Site Number 410002

    Seoul, South Korea

  • Investigational Site Number 724004

    Badalona, Spain

  • Investigational Site Number 724001

    Barcelona, Spain

  • Investigational Site Number 724003

    Madrid, Spain

  • Investigational Site Number 724002

    Valencia, Spain

  • Investigational Site Number 826001

    Belfast, United Kingdom

  • Investigational Site Number 826006

    Birmingham, United Kingdom

  • Investigational Site Number 826003

    London, United Kingdom

  • Investigational Site Number 826004

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.